Siwa Therapeutics
  • Home
  • Leadership
  • Science
  • Data
  • Media
    • News
    • Videos
  • Partners
  • Contact

Month: September 2019

Home / 2019 / September
26Sep 2019 by Andrew Premovich

In the News: Forbes

In The News
SIWA therapeutics was mentioned in an article at Forbes! See what they had to say about senolytic therapies and the future of aging.
Read More

Recent Posts

  • Listen to our founder and CEO, Lewis Gruber discuss SIWA and 318H!
  • In The News: Supertrends
  • Press Release: SIWA Therapeutics Grows Leadership Team with Appointment of Gabriela Rossi, Ph.D.
  • In The News: Startup.info Interview
  • In The News: BIOSPACE

Archives

  • April 2021
  • October 2020
  • September 2020
  • June 2020
  • May 2020
  • March 2020
  • February 2020
  • September 2019
  • March 2019
  • April 2018
  • January 2018
  • June 2017
  • May 2017
  • October 2016

Categories

  • Events
  • In The News
  • News
  • Press Releases
  • Uncategorized

About Us

SIWA’s 318H monoclonal antibody targets a biomarker on cancer cells, senescent cells, and microbially-infected cells. Our initial focus is on gastrointestinal and related diseases that are eligible for FDA Fast-tracking. We expect to file our first IND in late 2021 jointly with a major institution in pancreatic cancer/cachexia. ***

Recent News

  • Listen to our founder and CEO, Lewis Gruber discuss SIWA and 318H!
  • In The News: Supertrends
  • Press Release: SIWA Therapeutics Grows Leadership Team with Appointment of Gabriela Rossi, Ph.D.

JOIN OUR MAILING LIST

Navigation

  • Home
  • Leadership
  • Science
  • Data
  • Media
    • News
    • Videos
  • Partners
  • Contact